

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

COMPLETION OF REGISTRATION OF THE FIRST GRANT OF THE 2022 SHARE OPTIONS INCENTIVE SCHEME

References are made to the announcements of the Company dated 30 August 2022, 21 September 2022 and 7 November 2022 and the circular of the Company dated 27 September 2022 (the “**Circular**”) in relation to, among others, the proposed adoption of the Incentive Scheme. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meaning as those defined in the Circular.

On 7 November 2022, the Board has considered and approved the First Grant of 17,973,500 Share Options to 1,026 Incentive Participants. The date of the First Grant is 7 November 2022.

On 23 November 2022, the First Grant has completed registration. The abbreviation of the Share Options: Livzon JLC3. The code of the Share Options is 037312.

By order of the Board

麗珠醫藥集團股份有限公司

Livzon Pharmaceutical Group Inc.*

Yang Liang

Company Secretary

Zhuhai, China

23 November 2022

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

** For identification purpose only*